

Top 46-50

09 June 2011 | News

Image not found or type unknown



Image not found or type unknown



Synchron Research Services

CMD
Dr Shivprakash

46

Business: Provides clinical research services from phase I to phase IV

Start-up Year: 1998

Address: The Chambers, 3rd Floor, Sarkhej-Gandhinagar Highway, Bodakdev, Ahmedabad - 380 054

Tel: +91-79-26853419, 26840427

Fax: +91-79-26853415

Website: www.synchronresearch.com

Synchron Research Services reported an estimated revenue of ₹63 crore in 2010-11 as compared to previous year's estimated revenue of ₹57 crore. It is a leading CRO in India, which provides a broad range of clinical research services from phase I to phase IV, including bioavailability, bioequivalence, pharmacokinetic, pharmacodynamic studies, dermato-pharmacokinetics, bioanalysis, statistical analysis, data management and pharmacovigilance. It has a 30-bed facility in Bangkok called Bio-Innova Synchron Research to serve the Asia Pacific region, which was formed by a joint venture between Bio-innova and Synchron Research. Synchron also acquired Innovance, an Ahmedabad-based start-up CRO having a clinical research facility. The new clinical facility is spread across 18,000 sq ft on a single floor, with three different volunteer housing areas. The new 80 beds will be an addition to the already existing 90 beds in the existing facility, thus totaling to 200 beds across Asia.

Revenue:  63 crore*

 Image not found or type unknown

JK Agri Genetics

President
Mr P S Dravid

Business: Involved in R&D and marketing of agri biotech products

Start-up Year: 1989

47

Address: 1-20-177, 4th Floor, Varun Towers, Begumpet, Hyderabad-500016

Tel: +91-40-66316858

Fax: +91-40-27764943

Website: www.jkseeds.net

Revenue:  50.66 crore*



JK Agri Genetics Limited (JKAL), an erstwhile division of JK Tyre & Industries, clocked a total turnover of  50.66 crore in 2010-11 when compared with the last year's revenue of  32.50 crore. The company is focused on R&D, production, processing and marketing of hybrid seeds of sorghum, pearl millet, maize, cotton, rice, sunflower, tomato, okra and hot pepper. There are many hybrids marketed by the company, including fast-moving hybrids such as JK 99, JK Durga, JK 666, JK Indra, JK Varun (555), JK Chamundi. The firm has a team of 15 committed scientists working on different areas of biotechnology. JKAL is planning to diversify its research into medicinal and aromatic plants in core activities such as cultivation, contract farming, varietal development, quality extract production and chemical & DNA finger printing. JKAL is building up its R&D as well as marker-assisted selection with novel traits with the help of biotechnology tools.

 Image not found or type unknown

Wockhardt

Chairman
Mr Habil F Khorakiwala

Business: Pharmaceutical and biotechnology business

Start-up Year: 1960

48

Address: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai-400051

Tel: +91-22-26596258

Fax: +91-22-26596801

Website: www.ockhardt.in

Revenue:  50 crore*




Wockhardt, the first company in Asia to launch its recombinant human insulin product, Wosulin, in 2003, recorded an estimated biotech revenue of  50 crore for 2010-11. In Feb 2011, Wockhardt entered into a strategic global alliance with Sheffield Bio-Science, a Kerry Group Business from the US, under which the latter will have exclusive sales and distribution rights to supply the recombinant insulin to the cell culture markets worldwide. Wockhardt announced in 2009 that it was experiencing liquidity crisis and was reportedly facing a debt burden of more than  3,000 crore. Following this, there were talks that the company would sell its biotech division. Companies like Pfizer and Sanofi Aventis were on the run to acquire this unit, and its valuations reached a whopping  250 crore. Presently, the firm's R&D is based in Aurangabad & Mumbai; Negma Laboratories in France; Morton Grove Pharmaceuticals in Illinois, US; Pinewood, Ireland and in UK.

 Image not found or type unknown



Max Neeman International

CEO
Dr Ajoy Kumar

Business: Clinical research services

Start-up Year: 2001

49

Max Neeman International, a subsidiary of the Max India Group, registered a growth of 21 percent from  40 crore in FY 2009-10 to  48.4 crore in FY 2010-11. The firm offers a full range of clinical research services with focus on phase I-IV trials for drugs, devices, nutraceuticals and cosmetics in compliance with ICH GCP standards. It is based out of six regional offices and has 175 active sites in 22 cities, with access to over 900 GCP trained investigators. Max Neeman is a ISO 9001:2008 and ISO 27001 certified organization. The number of trials of the firms reached 200 and the CRO has a total client base of 65 companies across the globe. Max Neeman has consistently maintained a patient retention rate of above 98 percent across multiple therapeutic areas for all its studies. Max Neeman successfully completed four FDA audits

Address: Max House, 1 Dr Jha Marg, Okhla III, New Delhi-110020

Tel: +91-11-40772100

Fax: +91-11-28322846

Website: www.neeman-medical.com

Revenue: 48.4 crore



Clinigene International

COO
Dr Abhijit Barve

Business: Clinical research

Start-up Year: 1996

50

Address: Clinigene House, Tower 1, Semicon Park, Electronic City, Phase II, Bangalore-560100

Tel: +91-80-28082808

Fax: +91-80-28083150

Website: www.clinigeneintl.com

Revenue: 43 crore

Clinigene International, the full service clinical research arm of biotech major, Biocon, registered a turnover of 43 crore in FY 2010-11 as compared to 39 crore in the FY 2009-10. In the year 2010, studies conducted by Clinigene were successfully audited by the USFDA and EMA without Form 483 or critical findings. In addition to the standard service platforms, the company has identified several more specialized areas, such as patient-based early studies, complex BA/BE studies and bio-analytical services, where customers are now seeking CRO support. The new areas of focus for Clinigene include biomarker development, data management and pharmacovigilance. Clinigene is India's first CAP accredited central laboratory and has also received NABL accreditation. The company has evolved and adapted its capability platforms and service offerings against a background of continued macro market pressures.